Biological basis for the clinical use of interferon

F Dianzani

Abstract
Interferons are proteins produced by certain cells in response to stimuli such as foreign cells (including tumour cells), bacteria, and viral antigens. They interact both with the interferon producing cells and other cells through production of effector proteins. There are three main types of interferons, known as α, β, and γ, which have direct antiviral and immunomodulatory effects. Antiviral effects may include inhibition of viral replication, protein synthesis, maturation, or release from infected cells. Immunomodulating effects may include enhancement of macrophage, cytotoxic T cell, and natural killer cell activity. In chronic viral hepatitis, the precise mechanisms of action of α interferon are not yet certain. Patients with chronic hepatitis B, however, have been shown to lack endogenous interferon production; those who respond to α interferon treatment show a characteristic peak in serum amino-transferase activity before resolution of the infection, indicating an immune reaction. In chronic hepatitis C, the antiviral effect may be more important; patients who respond to α interferon tend to have higher values of 25'-oligo adenylate synthetase, an enzyme induced by interferons that breaks down viral RNA. The clinical relevance of anti-interferon neutralising antibodies produced by some patients during interferon treatment has yet to be firmly established.

( Gut 1993; supplement: S74-S76 )

Interferons also act on cell functions, including cell differentiation and modulation of the immune system. In this way, interferon may inhibit cell replication but enhance the functions of fully differentiated cells, including an increase in antibody production and macrophage and cytotoxic cell activity. For example, macrophages cultivated in the presence of Candida albicans show greatly enhanced phagocytic activity when interferon is added. In another study of cultures infected with HIV, there was little inhibition of viral growth with interferon alone (even at high doses) but the addition of peripheral blood mononuclear leucocytes from a healthy donor enhanced strongly the antiviral effect. Interferon in this way has an indirect effect by enhancing cytotoxic T cell activity. Similarly, natural killer cell activity has been shown to be increased by interferons, particularly γ interferon. Interferons are also able to modulate the expression of other cytokine receptors on cells, including interleukin 2 and tumour necrosis.
factor \( \alpha \),\(^a\)\(^1\)\(^2\) and can increase expression of the Fc receptor on macrophages.\(^a\)\(^3\) If these immunomodulatory effects of interferon are to succeed, a fully reactive immune system is imperative. The lack of efficacy seen in immunosuppressed patients is evidence of this.

**Dose response relation**

The amount of interferon given is also important. Data from Norway have shown that certain doses of interferon enhanced both phagocytic and natural killer cell activity, while higher doses decreased this activity.\(^a\)\(^4\) Thus, there may be an optimal dose of interferon which may vary from one patient to another. In studies of patients with renal cell carcinoma treated with doses of \( \alpha \) interferon from 3 to 150 million units (MU), the complete response rate overall was less than 2% and the complete plus partial response rate less than 20%.\(^a\)\(^5\) Patients treated with more than 20 MU, however, were found to have a response rate of about 13%, while twice as many responded to treatment with 10 to 20 MU. Even those treated with less than 10 MU had a significantly better response rate compared with the patients on a high dose. Thus, for immune modulation, a high dose of interferon may not be necessary or even helpful.

**Interferon in viral hepatitis**

Of the three interferons, \( \alpha \) interferon has shown the most benefit in patients with chronic viral hepatitis. In chronic hepatitis B patients who respond to treatment with \( \alpha \) interferon, there is an immediate reduction in viral DNA and usually serum aminotransferase activities, followed by a sudden peak in aminotransferase activity about two to three months after the treatment is started. This suggests that the initial response is because of interferon’s direct antiviral activity while the second phase is mediated by an immune mechanism. This effect may be because it has been found that interferons enhance expression of both class I and II HLA antigens in virus infected cells.\(^a\)\(^6\)\(^1\)\(^7\) In vitro studies have shown that \( \alpha \) interferon enhances HLA 1 antigen expression, which in turn allows viral antigens to be presented on the cell surface, resulting in recognition and lysis by cytotoxic cells.\(^a\)\(^8\) HLA 2 antigen expression may also be increased, which may result in stimulation of CD4+ lymphocytes and ultimately antibody production by B cells,\(^a\)\(^8\) but further studies are needed to confirm the relation of these. Interferon’s enhancement of cytotoxic T cell and natural killer cell activity described above also plays an important part in defeating hepatitis B infection.

Studies in patients with chronic hepatitis B have shown that at least some of them have a defect in their endogenous interferon production,\(^a\)\(^9\)\(^1\)\(^0\) providing a rationale for interferon treatment in this disease. In particular, leukocytes from children with chronic hepatitis B do not produce interferon in response to viral stimulation while control cells show a good interferon response.\(^a\)\(^9\)

The liver damage seen in chronic hepatitis C infection seems to be caused by a direct cytopathic effect of the virus itself rather than by an immune response, as in hepatitis B. Thus the antiviral activity of interferon may be more important than its immunomodulating effects in this setting. Moreover, as the hepatitis C virus seems to be very sensitive to \( \alpha \) interferon, a higher rate of responders to lower interferon doses is often seen. Since the interferon induced antiviral state decays with time after removal of interferon, however, relapses are often seen in the patients responding to treatment when the treatment is stopped. Usually the response is established again by interferon being reintroduced.

**Variables affecting response to interferon**

The specific type of viral infection may influence the role of, and response to, interferon. Viruses that kill the cell before being released usually cause very acute infections and are not good targets for interferon. Viruses that mature on the cell surface, however, need to keep the cell alive for as long as possible; in this case, interferon can have both a direct effect on viral growth and an indirect effect mediated by viral antigen expression on the cell membrane. In other infections, the virus does not replicate independently and the viral genome becomes integrated into that of the host cell (as in long standing hepatitis B infections). Here, the only possible effect is that mediated by viral antigen expression — that is, an immune response rather than a direct antiviral effect. Studies have shown, however, that interferon does not inhibit expression of viral sequences once integrated into cellular DNA.\(^a\)\(^2\)\(^1\)\(^2\)

The pharmacokinetics of interferon inevitably affect its activity. For example, treatment with \( \alpha \) interferon results in high concentrations in the liver and kidneys but poor distribution to solid tumours.\(^a\)\(^2\)\(^3\) Therefore, a reduction in tumour burden must be achieved to allow interferon to reach the transformed cells. Interferon induced resistance to viral infection in a cell continues for a time even when the interferon is stopped. The effect lasts longer following prolonged treatment with interferon than it does following a pulse of interferon.\(^a\)\(^2\)\(^4\) With high doses of interferon, however, the end result may be down regulation of the interferon receptor leading to the lack of response to interferon seen in previous studies. This implies that the continuous presence of interferon in the circulation is not only useless but it may even be detrimental.

**Predictors of response during \( \alpha \) interferon treatment**

Patients with chronic hepatitis B who respond well to \( \alpha \) interferon treatment show the typical clinical course described above, with a characteristic peak in serum aminotransferases just before resolution of the infection. Those who do not show this peak are less likely to have a complete response, even if some modulation of
TABLE I Incidence of antibodies in patients treated with recombinant interferon (rIFN-alfa-2a or rIFN-alfa-2b) or lymphoblastoid interferon (IFN-alfa-N1) (from Antonelli et al)1

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Neutralising antibody positive/tested (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>rIFN-alfa-2a</td>
<td>15/74 (20-2)*</td>
</tr>
<tr>
<td>rIFN-alfa-2b</td>
<td>10/144 (6-9)*</td>
</tr>
<tr>
<td>rIFN-alfa-N1</td>
<td>1/78 (1-2)**</td>
</tr>
</tbody>
</table>

*p<0.01

TABLE II Effect of antibody to interferon-alfa-2a in patients with chronic hepatitis C (from Dianzani et al)4

<table>
<thead>
<tr>
<th>Number of patients</th>
<th>Anti-IFN neutralising antibody assay</th>
</tr>
</thead>
<tbody>
<tr>
<td>Responders</td>
<td>Anti-IFN neutralising antibody assay</td>
</tr>
<tr>
<td>30 (63-8)</td>
<td>26 (81-3)</td>
</tr>
<tr>
<td>17 (36-2)</td>
<td>6 (18-7)</td>
</tr>
<tr>
<td>Non-responders</td>
<td>Anti-IFN neutralising antibody assay</td>
</tr>
<tr>
<td>2 (6-9)</td>
<td>11 (73-4)**</td>
</tr>
</tbody>
</table>

*p=0.0004 compared with responders.

aminotransferases has been seen. Studies have also shown that patients with chronic hepatitis C who respond to treatment with α interferon have a higher percentage increase in 25S oligoadenylate synthetase production than those who do not respond, and that this increase persists during a six month period of study.

Induction of anti-interferon neutralising antibodies may also influence response. One study showed that recombinant interferon alfa-2a (ROFERON, Roche, Basle) induced neutralising antibodies in about 20% of patients with chronic viral hepatitis.35 Only about 6% of those treated with recombinant interferon alfa-2b (INTRON A, Schering-Plough, Kenilworth) produced antibodies and even fewer of those given natural α interferon (Table I). Furthermore, the titre of neutralising antibodies was much higher in those receiving alfa-2a compared with those on alfa-2b or natural interferon.

The clinical relevance of these antibodies has yet to be firmly established. In a study of patients with chronic hepatitis C treated with interferon alfa-2a, 30 responded with normalisation of serum aminotransferase activity.36 Among these responders, 26 were negative for neutralising antibodies and only four were positive. Among those who did not respond, this ratio was reversed, suggesting that neutralising antibody formation may be a factor for non-response to interferon alfa-2a (Table II). The clinical course is apparently unaffected in some patients, however, who do develop antibodies to interferon alfa-2a. In some of these patients, it may be that the disease was already cured by the time the antibodies were produced.

Conclusions

Interferons have a wide range of effects, including direct anti-viral and anti-tumour responses as well as modulation and enhancement of the cell mediated immune system. In chronic viral hepatitis, α interferon treatment has beneficial effects although the precise mechanisms of action are not yet certain. There are indications, however, suggesting that in chronic hepatitis B α interferon may act as both an antiviral and immunomodulatory agent, while in chronic hepatitis C the main action seems to be antiviral.


Biological basis for the clinical use of interferon.

F Dianzani

Gut 1993 34: S74-S76
doi: 10.1136/gut.34.2_Suppl.S74

Updated information and services can be found at:
http://gut.bmj.com/content/34/2_Suppl/S74

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections
Hepatitis B (88)
Hepatitis C (160)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/